Skip to main content

Posters, Oral Presentation

Showing 2 of 4

New

RSV hospitalisation burden in high-risk infants across two seasons of universal prophylaxis with nirsevimab. The NIRSE-GAL study.

Confidential. For use by Medical Affairs for scientific exchange purposes only. Do not copy or distribute. Some information may not be consistent with the approved product labelling for the product(s) being discussed; this information may relate to the indication or use, dosage and administration, patient population, combination use, or other potential unapproved uses. No conclusions regarding safety and efficacy can be made for such uses.